| Literature DB >> 21174625 |
Jeremy K Nicholson1, Ian D Wilson, John C Lindon.
Abstract
This article introduces and reviews the concept of pharmacometabonomics, with recent experimental exemplifications of the approach being described and discussed. Pharmacometabonomics seeks to predict the response of an individual to a stimulus (e.g., drug, toxin, surgery, nutrition and so on) prior to the stimulus or other perturbation. It is an integral part of top-down systems biology which aims to improve understanding of phenotypic differences and the impact of beneficial and pathological interventions. The pharmacometabonomic concept is also integral to the understanding of mammalian-gut microbiome cometabolic interactions and their consequences, including the impact on disease and therapy. Although the subject is only at an early stage and requires further exemplification and validation, the approach has major implications for improved efficiency in drug discovery efforts, for example, by enabling more careful selection of animals in preclinical studies, for better stratification of patients in drug clinical trials and for individualized therapies. It could also find application in population-wide large cohort studies and in studies of nutrition where it would allow the elucidation of health risk factors and provide easily measured surrogate biomarkers.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21174625 DOI: 10.2217/pgs.10.157
Source DB: PubMed Journal: Pharmacogenomics ISSN: 1462-2416 Impact factor: 2.533